company background image
POLB

Poolbeg Pharma AIM:POLB Stock Report

Last Price

UK£0.095

Market Cap

UK£47.5m

7D

4.4%

1Y

22.6%

Updated

04 Feb, 2023

Data

Company Financials +

POLB Stock Overview

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom.

POLB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Poolbeg Pharma PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Poolbeg Pharma
Historical stock prices
Current Share PriceUK£0.095
52 Week HighUK£0.11
52 Week LowUK£0.04
Beta0
1 Month Change31.94%
3 Month Change43.94%
1 Year Change22.58%
3 Year Changen/a
5 Year Changen/a
Change since IPO-11.63%

Recent News & Updates

Recent updates

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Jul 12
Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Shareholder Returns

POLBGB PharmaceuticalsGB Market
7D4.4%0.4%1.8%
1Y22.6%4.1%-3.7%

Return vs Industry: POLB exceeded the UK Pharmaceuticals industry which returned 1.1% over the past year.

Return vs Market: POLB exceeded the UK Market which returned -3.1% over the past year.

Price Volatility

Is POLB's price volatile compared to industry and market?
POLB volatility
POLB Average Weekly Movement12.6%
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement5.1%
10% most volatile stocks in GB Market11.0%
10% least volatile stocks in GB Market2.7%

Stable Share Price: POLB is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: POLB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
20217Jeremy Skillingtonhttps://www.poolbegpharma.com

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.

Poolbeg Pharma PLC Fundamentals Summary

How do Poolbeg Pharma's earnings and revenue compare to its market cap?
POLB fundamental statistics
Market CapUK£47.50m
Earnings (TTM)-UK£3.11m
Revenue (TTM)n/a

0.0x

P/S Ratio

-15.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
POLB income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£3.11m
Earnings-UK£3.11m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0062
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did POLB perform over the long term?

See historical performance and comparison